Press release April 27th 2016

ArcDia International releases new product line for diagnostics of acute gastroenteritis

Turku, April 27th 2016 – ArcDia International Oy Ltd. has launched a new product line for rapid diagnostics of acute gastroenteritis. ArcDia Group’s mariPOC® is the leading test system in rapid diagnostics of respiratory infections in Finland. mariPOC® Gastro test extends the selection of mariPOC® multianalyte tests.

mariPOC® Gastro test recognizes five common gastroenteritis pathogens and it is more accurate than traditional tests. Because of its rapidity and ease of use mariPOC® Gastro suits well for emergency units in addition to central microbiology laboratories. Rapid result reporting enables better treatment of patients and prevents spreading of epidemics.

mariPOC® Gastro test is an outcome of productive research co-operation of Finnish research institutes under the SHOK program financed by TEKES (the Finnish Funding Agency for Innovation) and health technology industry.

“The SHOK program has been an excellent example of the strength of Finnish high-tech society”, says R&D Director of ArcDia, Dr. Janne Koskinen. “Development of the mariPOC® Gastro test was a remarkable investment for ArcDia. Without the co-operation with SHOK research consortium we would not have been able to solve the challenges related to gastroenteritis diagnostic test development in such a tight schedule”, Koskinen continues.

Export of Finnish health technology has been increasing lately. ArcDia’s new product line is expected to increase the company’s export business especially outside of Scandinavia where gastro intestinal infections are more common. ArcDia will continue to expand the mariPOC® product portfolio in future, as it is the key to successful overseas market penetration.

mariPOC®
mariPOC® is an automatic test system designed for rapid testing of acute infectious diseases. mariPOC® recognizes most significant respiratory tract, pharynx and intestine located pathogens. mariPOC® is a market leader in automated testing of respiratory tract infections. mariPOC® is known for its accuracy and efficiency.

ArcDia

ArcDia International Oy Ltd. develops, manufactures and markets mariPOC® worldwide. Company was funded in 2008 and employs 28 people at the head quarter in Turku, Finland. (www.arcdia.com)

More information:
Ida Koho
Marketing Manager
ArcDia International Oy Ltd.
Email: ida.koho@arcdia.com
Mobile: +358 40 531 6263